Stock Analyses

Model-driven valuations for thousands of US-listed stocks, built from SEC EDGAR filings. Click any card to see the full analysis.

All sectors 6,479 Financial Services 1,900 Healthcare 1,116 Technology 1,079 Industrials 668 Consumer Cyclical 490 Basic Materials 337 Consumer Defensive 248 Communication Services 213 Utilities 183 Energy 165 Real Estate 80

1,116 stocks · page 7 of 19

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.

enGene Therapeutics Inc.

enGene Therapeutics Inc.

Deeply undervalued

Discount 65% Return to IV: +183.7%

Market implies -16.6%/yr vs model +12.1% · below model

Ensysce Biosciences, Inc.

Deeply undervalued

Discount 82% Return to IV: +459.3%

Market implies -39.1%/yr vs model +9.5% · below model

ENSIGN GROUP, INC

Deeply undervalued

Model IV$459.50

Discount 62% Return to IV: +166.0%

Market implies -0.3%/yr vs model +15.4% · below model

ENANTA PHARMACEUTICALS INC

Entera Bio Ltd.

Market implies +131.4%/yr vs model +2.0% · above model

Enveric Biosciences, Inc.

Deeply undervalued

Discount 36% Return to IV: +57.3%

Market implies -8.2%/yr vs model +31.4% · below model

EUPRAXIA PHARMACEUTICALS INC.

Equillium, Inc.

Market implies +2.1%/yr vs model +15.0% · below model

Ernexa Therapeutics Inc.

Market implies +35.2%/yr vs model +15.0% · above model

Ernexa Therapeutics Inc.

Market implies -13.1%/yr

Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc.

Esperion Therapeutics, Inc.

Deeply undervalued

Discount 62% Return to IV: +164.1%

Market implies -12.4%/yr vs model +50.0% · below model

ESTABLISHMENT LABS HOLDINGS INC.

Market implies +29.1%/yr vs model +13.6% · above model

Eton Pharmaceuticals, Inc.

Premium +88% Return to IV: -46.8%

Market implies +0.7%/yr vs model +38.3% · below model

EUDA Health Holdings Ltd

Deeply overvalued

Premium +41% Return to IV: -28.8%

Market implies -8.3%/yr vs model +10.6% · below model

EUDA Health Holdings Ltd

Market implies -50.0%/yr

Discount 1% Return to IV: +1.5%

Market implies +0.4%/yr vs model +50.0% · below model

Edwards Lifesciences Corp

Deeply overvalued

Premium +74% Return to IV: -42.4%

Owner yield 1.5% 10-yr IRR -5.6% · moderate

Market implies +13.2%/yr vs model +7.5% · above model

Edgewise Therapeutics, Inc.

Deeply undervalued

Discount 37% Return to IV: +57.9%

Owner yield 3.9% 10-yr IRR 11.4% · grower

Market implies +5.7%/yr vs model +15.2% · below model

Market implies +95.8%/yr vs model +15.0% · above model

National Vision Holdings, Inc.

Deeply overvalued

Premium +75% Return to IV: -42.8%

Owner yield 4.4% 10-yr IRR 7.6% · moderate

Market implies +13.0%/yr vs model +7.6% · above model

FATE THERAPEUTICS INC

Market implies +92.2%/yr vs model +2.0% · above model

Fortress Biotech, Inc.

Deeply overvalued

Premium +107% Return to IV: -51.8%

Market implies +6.0%/yr vs model +2.0% · above model

Fortress Biotech, Inc.

Market implies +29.3%/yr vs model +5.5% · above model

FibroBiologics, Inc.

Forte Biosciences, Inc.

FOCUS UNIVERSAL INC.

Market implies +55.0%/yr vs model +2.0% · above model

4D Molecular Therapeutics, Inc.

Deeply overvalued

Premium +60% Return to IV: -37.4%

Market implies +5.4%/yr vs model +47.4% · below model

ENvue Medical, Inc.

Deeply undervalued

Discount 9% Return to IV: +10.4%

Market implies -7.8%/yr vs model +10.8% · below model

FREQUENCY ELECTRONICS INC

Market implies +150.0%/yr vs model +15.0% · above model

Market implies +46.1%/yr vs model +18.1% · above model

FENNEC PHARMACEUTICALS INC.

Market implies +32.2%/yr vs model +15.0% · above model

Foghorn Therapeutics Inc.

Deeply overvalued

Premium +231% Return to IV: -69.8%

Market implies +21.7%/yr vs model +50.0% · below model

Fulgent Genetics, Inc.

Deeply overvalued

Premium +150% Return to IV: -60.1%

Market implies +8.1%/yr vs model +2.0% · above model

FILANA THERAPEUTICS, INC.

Fresenius Medical Care AG

Deeply undervalued

Model IV$106.03

Discount 79% Return to IV: +374.4%

Owner yield 17.3% 10-yr IRR 29.6% · moderate

Market implies -15.0%/yr vs model +6.5% · below model

FITLIFE BRANDS, INC.

Deeply undervalued

Discount 82% Return to IV: +452.1%

Owner yield 7.7% 10-yr IRR 21.8% · grower

Market implies -5.2%/yr vs model +24.5% · below model

Fortrea Holdings Inc.

Discount 9% Return to IV: +9.4%

Market implies +3.3%/yr vs model +2.0% · in line

Premium +21% Return to IV: -17.6%

Owner yield 6.7% 10-yr IRR 10.0% · steady

Market implies +5.4%/yr vs model +3.3% · in line

Fulcrum Therapeutics, Inc.

GALECTIN THERAPEUTICS INC

Gain Therapeutics, Inc.

Market implies +109.2%/yr vs model +15.0% · above model

Glucotrack, Inc.

CytoMed Therapeutics Ltd

GE HealthCare Technologies Inc.

Deeply overvalued

Premium +35% Return to IV: -26.0%

Owner yield 5.4% 10-yr IRR 9.1% · steady

Market implies +9.1%/yr vs model +5.9% · above model

Generate Biomedicines, Inc.

GEOSPACE TECHNOLOGIES CORP

Deeply overvalued

Premium +45% Return to IV: -30.8%

Market implies +6.4%/yr vs model +9.9% · below model

Market implies +141.6%/yr vs model +15.0% · above model